@article{ZieglerMeyerOtteetal.2022,
  author    = {Ziegler, Alice and Meyer, Hanna and Otte, Insa and Peters, Marcell K. and Appelhans, Tim and Behler, Christina and B{\"o}hning-Gaese, Katrin and Classen, Alice and Detsch, Florian and Deckert, J{\"u}rgen and Eardley, Connal D. and Ferger, Stefan W. and Fischer, Markus and Gebert, Friederike and Haas, Michael and Helbig-Bonitz, Maria and Hemp, Andreas and Hemp, Claudia and Kakengi, Victor and Mayr, Antonia V. and Ngereza, Christine and Reudenbach, Christoph and R{\"o}der, Juliane and Rutten, Gemma and Schellenberger Costa, David and Schleuning, Matthias and Ssymank, Axel and Steffan-Dewenter, Ingolf and Tardanico, Joseph and Tschapka, Marco and Vollst{\"a}dt, Maximilian G. R. and W{\"o}llauer, Stephan and Zhang, Jie and Brandl, Roland and Nauss, Thomas},
  title     = {Potential of airborne LiDAR derived vegetation structure for the prediction of animal species richness at Mount Kilimanjaro},
  series = {Remote Sensing},
  volume    = {14},
  journal   = {Remote Sensing},
  number    = {3},
  issn      = {2072-4292},
  doi       = {10.3390/rs14030786},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-262251},
  year      = {2022},
  abstract  = {The monitoring of species and functional diversity is of increasing relevance for the development of strategies for the conservation and management of biodiversity. Therefore, reliable estimates of the performance of monitoring techniques across taxa become important. Using a unique dataset, this study investigates the potential of airborne LiDAR-derived variables characterizing vegetation structure as predictors for animal species richness at the southern slopes of Mount Kilimanjaro. To disentangle the structural LiDAR information from co-factors related to elevational vegetation zones, LiDAR-based models were compared to the predictive power of elevation models. 17 taxa and 4 feeding guilds were modeled and the standardized study design allowed for a comparison across the assemblages. Results show that most taxa (14) and feeding guilds (3) can be predicted best by elevation with normalized RMSE values but only for three of those taxa and two of those feeding guilds the difference to other models is significant. Generally, modeling performances between different models vary only slightly for each assemblage. For the remaining, structural information at most showed little additional contribution to the performance. In summary, LiDAR observations can be used for animal species prediction. However, the effort and cost of aerial surveys are not always in proportion with the prediction quality, especially when the species distribution follows zonal patterns, and elevation information yields similar results.},
  language  = {en}
}
@article{GruenwaldPinkEgereretal.2022,
  author    = {Gr{\"u}nwald, Viktor and Pink, Daniel and Egerer, Gerlinde and Schalk, Enrico and Augustin, Marinela and Deinzer, Christoph K. W. and Kob, Viola and Reichert, Dietmar and Kebenko, Maxim and Brandl, Stephan and Hahn, Dennis and Lindner, Lars H. and Hoiczyk, Mathias and Ringsdorf, Uta and Hanker, Lars C. and Hempel, Dirk and De Rivas, Beatriz and Wismann, Tobias and Ivanyi, Philipp},
  title     = {Trabectedin for patients with advanced soft tissue sarcoma: a non-interventional, prospective, multicenter, phase IV trial},
  series = {Cancers},
  volume    = {14},
  journal   = {Cancers},
  number    = {21},
  issn      = {2072-6694},
  doi       = {10.3390/cancers14215234},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-290898},
  year      = {2022},
  abstract  = {This non-interventional, prospective phase IV trial evaluated trabectedin in patients with soft tissue sarcoma (STS) in real-life clinical practice across Germany. The primary endpoints were progression-free survival (PFS) rates at 3 and 6 months, as defined by investigators. Overall, 128 patients from 19 German sites were evaluated for efficacy and 130 for safety. Median age was 58.5 years (range: 23-84) and leiomyosarcoma was the most frequent histotype (n = 45; 35.2\%). Trabectedin was mostly used as second/third-line treatment (n = 91; 71.1\%). Median PFS was 5.2 months (95\% CI: 3.3-6.7), with 60.7\% and 44.5\% of patients free from progression at 3 and 6 months, respectively. Median overall survival was 15.2 months (95\% CI: 9.6-21.4). One patient achieved a complete and 14 patients a partial response, conferring an objective response rate of 11.7\%. Decreases in white blood cells (27.0\% of patients), platelets (16.2\%) and neutrophils (13.1\%) and increased alanine aminotransferase (10.8\%) were the most common trabectedin-related grade 3/4 adverse drug reactions. Two deaths due to pneumonia and sepsis were considered trabectedin-related. Trabectedin confers clinically meaningful activity in patients with multiple STS histotypes, comparable to that previously observed in clinical trials and other non-interventional studies, and with a manageable safety profile.},
  language  = {en}
}